Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

被引：9
|
作者：
Luger, Selina M. [1 ]
Sun, Zhuoxin [2 ]
Loghavi, Sanam [3 ]
Lazarus, Hillard M. [4 ]
Rowe, Jacob M. [5 ]
Tallman, Martin S. [6 ]
Pratz, Keith W. [7 ]
Litzow, Mark [8 ]
机构：
[1] Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA
[2] ECOG ACRIN Stat Ctr, Boston, MA USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[4] Case Western Reserve Univ, Sch Med, Cleveland, OH USA
[5] Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[8] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-128377
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1309
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin
    Jennifer Dotson
    Adee Elhamdani
    Ellen Petryna
    Muhammad Omer Jamil
    Mohamed Alsharedi
    International Journal of Hematology, 2019, 109 : 351 - 355
  • [32] Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
    Stone, R. M.
    Mandrekar, S. J.
    Sanford, B. L.
    Laumann, K.
    Geyer, S.
    Bloomfield, C. D.
    Thiede, C.
    Prior, T. W.
    Doehner, K.
    Marcucci, G.
    Lo-Coco, F.
    Klisovic, R. B.
    Wei, A.
    Sierra, J.
    Sanz, M. A.
    Brandwein, J. M.
    de Witte, T.
    Niederwieser, D.
    Appelbaum, F. R.
    Medeiros, B. C.
    Tallman, M. S.
    Krauter, J.
    Schlenk, R. F.
    Ganser, A.
    Serve, H.
    Ehninger, G.
    Amadori, S.
    Larson, R. A.
    Doehner, H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (05): : 454 - 464
  • [33] Hypophosphatemia in Midostaurin-Treated FLT3 Acute Myeloid Leukemia
    Chow, Timothy Michael
    Srialluri, Nityasree
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [34] Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
    Juanjuan Zhao
    Yongping Song
    Delong Liu
    Biomarker Research, 7
  • [35] Gilteritinib Reduces FLT3 Expression in Acute Myeloid Leukemia Cells
    Thai, Thi Lam
    Han, Sun-Young
    BIOMOLECULES & THERAPEUTICS, 2024, 32 (05) : 577 - 581
  • [36] Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
    Short, Nicholas J.
    Daver, Naval
    Dinardo, Courtney D.
    Kadia, Tapan
    Nasr, Lewis F.
    Macaron, Walid
    Yilmaz, Musa
    Borthakur, Gautam
    Montalban-Bravo, Guillermo
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Chien, Kelly S.
    Jabbour, Elias
    Nasnas, Cedric
    Huang, Xuelin
    Qiao, Wei
    Matthews, Jairo
    Stojanik, Christopher J.
    Patel, Keyur P.
    Abramova, Regina
    Thankachan, Jennifer
    Konopleva, Marina
    Kantarjian, Hagop
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (13) : 1499 - 1508
  • [37] Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia
    Chen, Nianci
    Pan, Jiajia
    Zhou, Yile
    Mao, Liping
    Lou, Yinjun
    Qian, Jiejing
    Xu, Gaixiang
    Wei, Juying
    Zhou, De
    Shou, Lihong
    Li, Huang
    Yan, Minchao
    Zeng, Hui
    Fan, Cuihua
    Wu, Gongqiang
    Feng, Weiying
    Tong, Hongyan
    Jin, Jie
    Wang, Huafeng
    BLOOD, 2023, 142
  • [38] A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Trial in Progress
    Short, Nicholas J.
    Ravandi, Farhad
    Daver, Naval
    Dinardo, Courtney D.
    Borthakur, Gautam
    Kadia, Tapan M.
    Yilmaz, Musa
    Issa, Ghayas C.
    Abramova, Regina
    Garza, Araceli Isabella
    Kantarjian, Hagop M.
    Abbas, Hussein A.
    BLOOD, 2024, 144
  • [39] Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
    Chew, Serena
    Mackey, Melissa C.
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [40] PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): A phase II clinical trial.
    Stone, RM
    Klimek, V
    DeAngelo, DJ
    Nimer, S
    Estey, E
    Galinsky, I
    Neuberg, D
    Yap, A
    Fox, EA
    Gilliland, DG
    Griffin, J
    BLOOD, 2002, 100 (11) : 86A - 86A
12345